Da Duan, Foster City, CA (US); Oscar Alvizo, Fremont, CA (US); Jovana Nazor, Milpitas, CA (US); Harvinder Chagger Maniar, Hayward, CA (US); James Nicholas Riggins, San Francisco, CA (US); Jonathan Vroom, South San Francisco, CA (US); Santhosh Sivaramakrishnan, Redwood City, CA (US); Hao Yang, Rahway, NJ (US); Anna Fryszkowska, New York, NY (US); Mark A. Huffman, Rahway, NJ (US); Joshua N. Kolev, Rahway, NJ (US); Iman Farasat, Rahway, NJ (US); Agustina Rodriguez-Granillo, Rahway, NJ (US); and Deeptak Verma, Rahway, NJ (US)
Assigned to Codexis, Inc., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Nov. 7, 2023, as Appl. No. 18/503,542.
Application 17/592,869 is a division of application No. 16/460,118, filed on Jul. 2, 2019, granted, now 11,274,286, issued on Mar. 15, 2022.
Application 18/503,542 is a continuation of application No. 17/592,869, filed on Feb. 4, 2022, granted, now 11,845,968.
Claims priority of provisional application 62/822,273, filed on Mar. 22, 2019.
Claims priority of provisional application 62/695,520, filed on Jul. 9, 2018.
Prior Publication US 2024/0076647 A1, Mar. 7, 2024
1. An engineered deoxyribose-phosphate aldolase comprising a polypeptide sequence having at least 95% sequence identity to SEQ ID NO: 2, or a functional fragment thereof, wherein said engineered deoxyribose-phosphate aldolase comprises a substitution in said polypeptide sequence of a methionine residue at position 47 relative to SEQ ID NO: 2, wherein said engineered deoxyribose-phosphate aldolase exhibits at least one improved property compared to the wild-type deoxyribose-phosphate aldolase of SEQ ID NO:2.